Kidney Sodium Content in Cardiorenal Patients

Launched by LONDON HEALTH SCIENCES CENTRE RESEARCH INSTITUTE OR LAWSON RESEARCH INSTITUTE OF ST. JOSEPH'S · Nov 18, 2019

Keywords

ClinConnect Summary

This clinical trial is studying how the sodium content in the kidneys of patients with both heart failure and kidney disease affects their response to diuretics, which are medications used to help remove excess fluid. Many patients with heart failure rely on diuretics, but some develop resistance, meaning the medication doesn’t work as well. This study aims to see if measuring the sodium levels in the kidneys can help predict which patients might have this resistance and how much diuretic they should be given to avoid complications.

To participate in this trial, individuals must be at least 18 years old, diagnosed with heart failure, and have been taking certain diuretics for at least a week. Participants will undergo magnetic resonance imaging (MRI) to measure their kidney sodium content. Those with diuretic resistance will receive an additional dose of diuretic, and researchers will observe any changes in sodium levels and how that affects their response to the medication. Overall, this study could help doctors provide better treatment for patients experiencing both heart and kidney issues.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria for Visit 1
• • Clinico-pathological diagnosis of heart failure
• • Age ≥ 18 years
• • Estimated GFR ≥ 15 mL/min/1.73m2
• • Receiving loop diuretics for at least a week at ≥ 40 mg/day (furosemide) or 2 mg/day (bumetanide), either orally or intravenously
• • Willing and able to provide consent
• • Inclusion Criteria for Visit 2 · Patients from visit 1 with diuretic resistance
• • Exclusion Criteria for Visit 1 Direct contraindications to MR scanning (implanted materials etc.)
• • Additional diuretic types other than spironolactone/epleronone/metolazone/finerenone
• • Liver disease with hepato-renal syndrome
• • Pregnant, breastfeeding or intending pregnancy
• • Kidney malformation leading to chronic kidney disease (for example polycystic kidney)
• • Unable to provide consent
• • Exclusion criteria for Visit 2
• • · Hypokalemia (serum potassium \<3.5 mmol/l)